Feeds:
Posts
Comments

Search Results for 'Pfizer'


Originally posted on New Drug Approvals:
? Inotuzumab ozogamicin RN: 635715-01-4 UNII: P93RUU11P7 Pfizer Inc., Oncology Institute Of Southern Switzerland  INNOVATOR http://chem.sis.nlm.nih.gov/chemidplus/rn/635715-01-4 MF 1680.6764 Oncological Treatment FDA grants breakthrough status for Pfizer’s leukaemia drug inotuzumab ozogamicin The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Pfizer’s investigational antibody-drug conjugate (ADC) inotuzumab ozogamicin to treat…

Read Full Post »


Merck and Pfizer Announces Global Strategic Alliance on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology Reporter: Aviva Lev-Ari, PhD, RN   Merck KGaA, Darmstadt, Germany, and Pfizer will jointly develop and commercialize Merck KGaA, Darmstadt, Germany,’s anti-PD-L1 Joint investment and combined strengths and capabilities will further maximize potential of Merck KGaA, Darmstadt, Germany,’s asset in the […]

Read Full Post »


Pfizer Cambridge Collaborative Innovation Events: ‘The Role of Innovation Districts in Metropolitan Areas to Drive the Global an | Basecamp Business. Reporter: Stephen J. Williams, Ph.D. Monday, September 8 2014 5:30pm – 7:00pm Other Time Presented by: Pfizer Cambridge/Boston Site Head       Event Details:Date/Time: Monday, September 8, 2014, 5:30-7PM EDTVenue: Pfizer Cambridge Seminar […]

Read Full Post »


Pfizer Abandons Bid for AstraZeneca Regardless of Valuation of its Future Financials: The Destiny of Drug R&D Pipelines – The Case of AstraZeneca Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 9/3/2014 ‘Back to normal’ for AstraZeneca CEO, despite Pfizer rumors BY BEN HIRSCHLER BARCELONA Tue Sep 2, 2014 8:59am EDT   (Reuters) – Though speculation is rife […]

Read Full Post »


AstraZeneca Makes Case Against the Friendly Pfizer’s Bid Reporter: Aviva Lev-Ari, PhD, RN US drug giant Pfizer has said commitments to preserve UK science jobs – if it wins a $106bn (£63bn) takeover of AstraZeneca – are legally binding. Pfizer has given a five-year promise to complete an AstraZeneca research centre in Cambridge, keep a […]

Read Full Post »


Reporter: Aviva Lev-Ari, PhD, RN Pfizer Inc. (PFE) Will Buy NextWave Pharmaceuticals for Up to $680 Million 10/22/2012 8:03:33 AM Pfizer Inc. | Jobs at Pfizer Inc. NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced its intention to acquire NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of unique products for the treatment of […]

Read Full Post »


Curator: Aviva Lev-Ari, PhD, RN Sunitinib brings Adult acute lymphoblastic leukemia (ALL) to Remission – RNA Sequencing – FLT3 Receptor Blockade https://pharmaceuticalintelligence.com/2012/07/09/sunitinib-brings-adult-all-to-remission-rna-sequencing/  

Read Full Post »


Curator: Aviva Lev-Ari, PhD, RN Sunitinib brings Adult acute lymphoblastic leukemia (ALL) to Remission – RNA Sequencing – FLT3 Receptor Blockade https://pharmaceuticalintelligence.com/2012/07/09/sunitinib-brings-adult-all-to-remission-rna-sequencing/  

Read Full Post »


RNA from the SARS-CoV-2 virus taking over the cells it infects: Virulence – Pathogen’s ability to infect a Resistant Host: The Imbalance between Controlling Virus Replication versus Activation of the Adaptive Immune Response Curator: Aviva Lev-Ari, PhD, RN – I added colors and bold face   See The Genome Structure of CORONAVIRUS, SARS-CoV-2 Reporter: Aviva […]

Read Full Post »


Is Remdesivir the miracle cure or a short term cure for COVID-19? Reporter: Irina Robu, PhD   Updated on 5/23/2020   New England Journal of Medicine Source Reference: Beigel JH, et al “Remdesivir for the Treatment of Covid-19 — Preliminary Report” N Engl J Med 2020; DOI: 10.1056/NEJMoa2007764. SOURCE https://www.nejm.org/doi/full/10.1056/NEJMoa2007764 Disclosures The trial was sponsored and […]

Read Full Post »

« Prev - Next »